Effective Due Diligence Assessments Improve Decision-Making
Due diligence is essential for successful biopharmaceutical investment, helping investors evaluate the true potential, risks, and value of drug development assets, projects, or biotech companies before committing their capital. Biopharmaceutical drug development is complex, highly regulated, and costly, with extended timelines for research, clinical trials, and regulatory approvals. Key components of due diligence include evaluating scientific validity, patent protections, competitive landscape, regulatory hurdles, reimbursement potential, management expertise, and financial health. A thorough examination of these factors enables investors to avoid costly mistakes, identify promising opportunities, and make informed decisions that maximize returns while managing risks.
Don’t Forget About Quality When Formulating Your Drug Development Plan
It is not uncommon for small biotech and biopharma startup companies to overlook Quality & Compliance when formulating their drug development plans and budgets. However, industry guidance from the International Conference on Harmonization (ICH) recommends that serious consideration be given to Quality Assurance (QA) very early in the process.
Current State of the Market for Antimicrobial Resistant (AMR) Medicines
While the world focuses on COVID-19, NGT’s Michael K. O’Brien and Philip Chu provide insight on the current state of the market for antimicrobial resistant (AMR) medicines. Read the article in Applied Clinical Trials Online.
Pharmaceutical, Device, BioTech: Building a Smart Business. (Part 2)
Alton Johnson is an industry leader and expert in pharmaceutical development, manufacturing, technology and business solutions. In his current consulting role, he develops strategies and solutions for clients in the areas of new product development, manufacturing, digital transformation, pharmaceutical technology, business development and compliance.
Pharmaceutical, Device, BioTech: Building a Smart Business. (Part 1)
Stacey Bruzzese welcomes Alton Johnson to the show to discuss companies adopting appropriate technologies and the Internet of Things.
Continuous Manufacturing: Opportunity to Be Agile to Demand & to Collaborate
The topic of continuous manufacturing has drawn considerable interest across all modalities of pharmaceutical manufacturing.
JLABS Webinar: Cracking the Commercialization Code
Register today for the May 7th JLABS Webinar: 4 defining steps that could unlock your life science technology’s commercialization potential.
2020 ISPE Annual Meeting & Expo
2020 ISPE Annual Meeting & Expo
1 – 4 Nov, Philadelphia Convention Center
Exhibitor: NGT BioPharma Booth # 712
2020 ISPE Facilities of the Future Conference
2020 ISPE Facilities of the Future Conference
Training 28 – 29 Jan | Conference 30 – 31 Jan 2020, San Francisco
Presenter: Michael O’Brien – Presentation title: Transformational Biopharmaceutical Manufacturing and Supply Paradigm
NGT BioPharma’s Sandy Farmer Ph.D. Tapped as Contributor to Congressional Report on Future of AI in Health Care
Approximately 20 to 25 participants representing pharma, biotech, academia, and government will come together in July to help define the future of AI in pharmaceutical R&D towards advancing health care in the United States. The specific focus will be to elucidate the opportunities and challenges for AI in drug discovery and development, with a broad view to the scientific, economic, ethical, legal and social aspects …